Clinical Trial Update: IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for IBI343 in combination with sintilimab and the SOX regimen for perioperative treatment of resectable, locally advanced gastric or gastro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• IBI343
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: CLDN18.2 Positive, Primary Gastric Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING